Nicholas Kitchin

23.2k citations

23 papers · 420 indexed · h-index 12

Co-authors: William C. Gruber Michael Watson Kathrin U. Jansen Jo Southern Michael W. Pride Yahong Peng Annaliesa S. Anderson Joseph Eiden
Topics: SARS-CoV-2 and COVID-19 Research (7 papers)Bacterial Infections and Vaccines (7 papers)Pneumonia and Respiratory Infections (6 papers)
Cited by: Microbiology Infectious Diseases Epidemiology
Journals: Clinical Infectious Diseases The Journal of Infectious Diseases Annals of Oncology
Partner nations: United Kingdom United States Germany

In The Last Decade

Nicholas Kitchin

22 papers receiving 398 citations

Peers

Countries citing papers authored by Nicholas Kitchin

Since Specialization

Citations

This map shows the geographic impact of Nicholas Kitchin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas Kitchin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas Kitchin more than expected).

Fields of papers citing papers by Nicholas Kitchin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicholas Kitchin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas Kitchin. The network helps show where Nicholas Kitchin may publish in the future.

Co-authorship network of co-authors of Nicholas Kitchin

This figure shows the co-authorship network connecting the top 25 collaborators of Nicholas Kitchin. A scholar is included among the top collaborators of Nicholas Kitchin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicholas Kitchin. Nicholas Kitchin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults 2025 ·Vaccines ·Angela R Branche,Mark J. Mulligan,(unknown),Orlando Puente,(unknown),Graham Crowther,Agnieszka Zareba,(unknown),Ingrid L. Scully,Emily Gomme,Kenneth Koury,Nicholas Kitchin,(unknown),Annaliesa S. Anderson,Alejandra Gurtman,Kelly Lindert	3
2	Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age 2025 ·Vaccines ·Joel M. Neutel,(unknown),(unknown),Kevin Cannon,(unknown),Ryan Newton,Emily Gomme,Wen Li,Federico Mensa,Özlem Türeci,Uğur Şahin,Kena A. Swanson,Iona Munjal,David Cooper,Kenneth Koury,Annaliesa S. Anderson,Alejandra Gurtman,Nicholas Kitchin	0
3	A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults Aged 65 to 85 Years 2023 ·The Journal of Infectious Diseases ·Shon Remich,Nicholas Kitchin,James T. Peterson,Ping Li,Michael W. Pride,(unknown),Annaliesa S. Anderson,William C. Gruber,Kathrin U. Jansen,Stephen Lockhart,Chris Webber	9
4	A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age 2023 ·Vaccine ·(unknown),Salim Bouguermouh,Kumar Ilangovan,Michael W. Pride,Chris Webber,Stephen Lockhart,Rupal Shah,Nicholas Kitchin,(unknown),Haiying Zhang,Qi Gao,(unknown),Annaliesa S. Anderson,William C. Gruber	9
5	1558O COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine 2021 ·Annals of Oncology ·Stephen J. Thomas,John L. Perez,Stephen Lockhart,Seetharaman Hariharan,Nicholas Kitchin,R.A. Bailey,Katherine Liau,Eleni Lagkadinou,Özlem Türeci,Uğur Şahin,Xia Xu,Samuel S. Dychter,Cuncun Lu,Teresa Gentile,William C. Gruber	9
6	Safety and immunogenicity of different Clostridioides (Clostridium) difficile vaccine formulations in two early phase randomized studies of healthy adults aged 50–85 years 2021 ·Vaccine ·Jody Lawrence,Nicholas Kitchin,Annaliesa S. Anderson,Michael W. Pride,Kathrin U. Jansen,William C. Gruber,Yahong Peng,(unknown),Charles Knirsch,Chris Webber	7
7	Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial 2021 ·Vaccine ·Stephen J. Thomas,John L. Perez,Stephen Lockhart,Hariharan Subramanian,Nicholas Kitchin,Ruth Bailey,Katherine Liau,Eleni Lagkadinou,Özlem Türeci,Uğur Şahin,Xia Xu,Kenneth Koury,Samuel S. Dychter,(unknown),Teresa Gentile,William C. Gruber	38
8	A Phase 2 Study Evaluating the Safety, Tolerability, and Immunogenicity of Two 3-Dose Regimens of a Clostridium difficile Vaccine in Healthy US Adults Aged 65 to 85 Years 2019 ·Clinical Infectious Diseases ·Nicholas Kitchin,Shon Remich,James T. Peterson,Yahong Peng,William C. Gruber,Kathrin U. Jansen,Michael W. Pride,Annaliesa S. Anderson,Charles Knirsch,Chris Webber	39
9	Meningococcal carriage in Dutch adolescents and young adults; a cross-sectional and longitudinal cohort study 2017 ·Clinical Microbiology and Infection ·(unknown),Merijn W. Bijlsma,Marlies A. van Houten,(unknown),Annaliesa S. Anderson,Joseph Eiden,Hao Li,Kathrin U. Jansen,Heather Jones,Nicholas Kitchin,Louise Pedneault,Elisabeth A. M. Sanders,Arie van der Ende	27
10	A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults 2016 ·Vaccine ·Eric Sheldon,Nicholas Kitchin,Yahong Peng,Joseph Eiden,William C. Gruber,Erik W. Johnson,Kathrin U. Jansen,Michael W. Pride,Louise Pedneault	56
11	Review of diphtheria, tetanus and pertussis vaccines in clinical development 2011 ·Expert Review of Vaccines ·Nicholas Kitchin	23
12	Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine 2009 ·Vaccine ·Nicholas Kitchin,Jo Southern,Rhonwen Morris,Ray Borrow,Anne Fiquet,(unknown),Stéphane Thomas,Elizabeth Miller	14
13	CO-ADMINISTRATION OF PENTAVALENT ROTAVIRUS VACCINE, ROTATEQ®, WITH MENINGOCOCCAL GROUP C CONJUGATE VACCINE: IMMUNOGENICITY AND SAFETY 2008 ·Archives of Disease in Childhood ·Timo Vesikari,Aino Karvonen,Nicholas Kitchin,Martine Baudin,Stéphane Thomas,(unknown),Anne Fiquet	1
14	A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age 2006 ·Vaccine ·Nicholas Kitchin,Jo Southern,Rhonwen Morris,(unknown),Keith Cartwright,Michael Watson,Elizabeth Miller	24
15	Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age 2006 ·Archives of Disease in Childhood ·Nicholas Kitchin,Jo Southern,Rob Morris,(unknown),Spencer A. Thomas,Michael Watson,Keith Cartwright,Emma R. Miller	54
16	Costs of running a universal adolescent hepatitis B vaccination programme 2005 ·Vaccine ·L A Wallace,David Young,A Brown,J. Claire Cameron,S. Faisal Ahmed,(unknown),William F. Carman,Nicholas Kitchin,Jonathan S. Nguyen‐Van‐Tam,David Goldberg	24
17	Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children 2004 ·Vaccine ·Clare L. Collins,(unknown),Noel McCarthy,Tracey Chantler,Laura A. Lane,(unknown),Linda Diggle,Jim Buttery,Nicholas Kitchin,E. Richard Moxon,Andrew J. Pollard	36
18	Universal hepatitis B vaccination of UK adolescents: a feasibility and acceptability study. 2002 ·PubMed ·(unknown),L A Wallace,S. Faisal Ahmed,(unknown),William F. Carman,(unknown),Nicholas Kitchin,Michael Watson,David Goldberg	14
19	Occurrence of adverse events following inadvertent administration of childhood vaccines 2002 ·Vaccine ·Tarik Derrough,Nicholas Kitchin	10
20	A randomised comparison of two inactivated hepatitis A vaccines, Avaxim™ and Vaqta™, given as a booster to subjects primed with Avaxim™ 2001 ·Vaccine ·P D Clarke,Nicholas Kitchin,(unknown)	12

About Nicholas Kitchin

Nicholas Kitchin is a scholar working on Microbiology, Infectious Diseases and Hepatology, having authored 23 papers that have together received 420 indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (7 papers), Bacterial Infections and Vaccines (7 papers) and Pneumonia and Respiratory Infections (6 papers). The work is most often cited by research in Microbiology (163 citations), Infectious Diseases (185 citations) and Epidemiology (285 citations). Nicholas Kitchin has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include William C. Gruber, Michael Watson, Kathrin U. Jansen, Jo Southern, Michael W. Pride, Yahong Peng, Annaliesa S. Anderson, Joseph Eiden, Louise Pedneault and Emma R. Miller. Their work appears in journals such as Clinical Infectious Diseases, The Journal of Infectious Diseases and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact